Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095029 plus pembrolizumab in MSI-H/dMMR advanced gastric or gastroesophageal junction adenocarcinoma
2023-507995-33-00Phase 2Authorised
- Sponsor
- Servier
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of sym021 and pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Servier. Primary endpoints: Incidence of dose-limiting toxicities, Frequency and severity of adverse events and laboratory abnormalities and 3 more. Planned start May 2024; status: authorised.
02
Drugs
sym021pembrolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-507995-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507995-33-00.